Ad hoc-Mitteilung gemäss Art. 53 des Kotierungsreglements der SIX Swiss Exchange
Die Schön Klinik SE startet am 1. Dezember 2022 ein freiwilliges Rückkaufangebot ihrer Anleihe.

DISCLAIMER – IMPORTANT
ELECTRONIC VERSIONS OF THE MATERIALS YOU ARE SEEKING TO ACCESS ARE BEING MADE AVAILABLE ON THIS WEBSITE IN GOOD FAITH AND ARE FOR INFORMATION PURPOSES ONLY.
In certain jurisdictions, the distribution of information in the connection with the offer described in the following pages (“Tender Offer”) may be restricted by law. Persons into whose possession this information comes are required to inform themselves about, and to observe, any such restrictions. The information on the following pages does not constitute an offer to buy or the solicitation of an offer to sell bonds (and tenders of bonds in the Tender Offer will not be accepted from bondholders) in any circumstances in which such offer or solicitation is unlawful.
No action has been or will be taken in any jurisdiction other than Switzerland by the Issuer that would, or is intended to, permit a redemption offer with respect to the Bonds or possession or distribution of the Information Memorandum or any other offering material, in any country or jurisdiction where action for that purpose is required.
In addition to the representations referred to below in respect of the United States, each holder participating in the Tender Offer will also be deemed to give certain representations in respect of the other jurisdictions referred to above and below. Any tender of bonds for purchase pursuant to the Tender Offer from a bondholder that is unable to make these representations shall not be made.
United States of America and U.S. Persons
The Tender Offer is not being made, and will not be made, directly or indirectly in or into, or by use of the mails of, or by any means or instrumentality of interstate or foreign commerce of, or of any facilities of a national securities exchange of, the United States. This includes, but is not limited to, facsimile transmission, electronic mail, telex, telephone, the internet and other forms of electronic communication. The Bonds may not be tendered in the Tender Offer by any such use, means, instrumentality or facility from or within the United States or by persons located or resident in the United States as defined in Regulation S of the U.S. Securities Act of 1933, as amended (the "Securities Act"). Accordingly, any documents or materials relating to the Tender Offer are not being, and must not be, directly or indirectly mailed or otherwise transmitted, distributed or forwarded (including, without limitation, by custodians, nominees or trustees) in or into the United States. Any purported tender of bonds in the Tender Offer resulting directly or indirectly from a violation of these restrictions will be invalid and any purported tender of bonds made by a person located in the United States or any agent, fiduciary or other intermediary acting on a non-discretionary basis for a principal giving instructions from within the United States will be invalid and will not be accepted.
The information on the following pages is not an offer to buy or sell, or a solicitation of an offer to sell or buy, any bonds or other securities in the United States. Securities may not be offered or sold in the United States absent registration under, or an exemption from the registration requirements of, the Securities Act.
Each holder of bonds participating in the Tender Offer will represent that it is not located in the United States and it is not participating in the Tender Offer from the United States, or it is acting on a non-discretionary basis for a principal located outside the United States that is not giving an order to participate in the Tender Offer from the United States. For the purposes of this and the above two paragraphs, "United States" means the United States of America, its territories and possessions (including Puerto Rico, the U.S. Virgin Islands, Guam, American Samoa, Wake Island and the Northern Mariana Islands), any state of the United States of America and the District of Columbia.
United Kingdom
The documents or materials relating to the Tender Offer are not being communicated, and such documents and/or materials have not been approved, by an authorised person for the purposes of section 21 of the Financial Services and Markets Act 2000. Accordingly, such documents and/or materials are not being distributed to, and must not be passed on to, the general public in the United Kingdom. The communication of such documents and/or materials as a financial promotion is only being made to, and may only be acted upon by, those persons in the United Kingdom falling within the definition of investment professionals (as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Financial Promotion Order")) or persons who are within Article 43 of the Financial Promotion Order or any other persons to whom it may otherwise lawfully be made under the Financial Promotion Order.
France
The Tender Offer is not being made, directly or indirectly, to the public in the Republic of France ("France"). No document or material relating to the Tender Offer has been or shall be distributed to the public in France and only (i) providers of investment services relating to portfolio management for the account of third parties (personnes fournissant le service d'investissement de gestion de portefeuille pour compte de tiers) and/or (ii) qualified investors (investisseurs qualifiés), other than individuals, acting for their own account, all as defined in, and in accordance with, Articles L.411-1, L.411-2 and D.411-1 of the French Code monétaire et financier, are eligible to participate in the Tender Offer. This Information Memorandum has not been and will not be submitted for clearance to nor approved by the Autorité des Marchés Financiers.
Kingdom of Belgium
None of the documents or materials relating to the Tender Offer have been submitted to or will be submitted for approval or recognition to the Belgian Financial Services and Markets Authority (Autoriteit voor financiële diensten en markten / Autorité des services et marchés financiers) and, accordingly, the Public Tender Offer may not be made in Belgium by way of a public offering, as defined in Articles 3 and 6 of the Belgian Law of 1 April 2007 on takeover bids as amended or replaced from time to time. Accordingly, the Tender Offer may not be advertised and the Tender Offer will not be extended or made available, directly or indirectly, to any person in Belgium other than "qualified investors" in the sense of Article 10 of the Belgian Law of 16 June 2006 on the public offer of placement instruments and the admission to trading of placement instruments on regulated markets, acting on their own account. Insofar as Belgium is concerned, Tender Offer documentation has been issued only for the personal use of the above qualified investors and exclusively for the purpose of the Tender Offer. Accordingly, the information contained in this Information Memorandum may not be used for any other purpose or disclosed to any other person in Belgium.
Republic of Italy
None of documents or materials relating to the Tender Offer has been or will be submitted to the clearance procedures of the Commissione Nazionale per le Società e la Borsa ("CONSOB") pursuant to Italian laws and regulations. The Tender Offer is being carried out in the Republic of Italy ("Italy") as an exempted offer pursuant to article 101-bis, paragraph 3-bis of the Legislative Decree No. 58 of 24 February 1998, as amended (the "Financial Services Act") and article 35-bis, paragraph 4 of CONSOB Regulation No. 11971 of 14 May 1999, as amended. Bondholders or beneficial owners of the bonds that are located in Italy may tender their bonds in the Tender Offer through authorised persons (such as investment firms, banks or financial intermediaries permitted to conduct such activities in Italy in accordance with the Financial Services Act, CONSOB Regulation No. 20307 of 13 February 2018, as amended from time to time, and Legislative Decree No. 385 of 1 September 1993, as amended) and in compliance with applicable laws and regulations or with requirements imposed by CONSOB or any other Italian authority.
Each intermediary must comply with the applicable laws and regulations concerning information du-ties vis-à-vis its clients in connection with the Bonds and/or the Tender Offer.
NICHT ZUR VERTEILUNG IN ODER AN EINE PERSON MIT AUFENTHALT ODER WOHNSITZ IN DEN VEREINIGTEN STAATEN VON AMERIKA, IHREN TERRITORIEN UND BESITZUNGEN (EINSCHLIESSLICH PUERTO RICO, DIE US-AMERIKANISCHEN VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND UND DIE NORTHERN MARIANA ISLANDS), EINEM BUNDESSTAAT DER VEREINIGTEN STAATEN VON AMERIKA UND DEM DISTRICT OF COLUMBIA (DIE "VEREINIGTEN STAATEN") ODER EINER ANDEREN JURISDIKTION, IN DER DIE VERBREITUNG DIESES DOKUMENTES UNZULÄSSIG IST
Mitteilungen zum Download / Notice for download
Ad hoc-Mitteilung gemäss Art. 53 des Kotierungsreglements der SIX Swiss Exchange
1. Dezember 2022
SCHÖN KLINIK SE
(die "Emittentin")
Die Emittentin startet heute ein freiwilliges Rückkaufangebot (das "Rückkaufangebot") in Bezug auf ihre im Jahr 2019 ausgegebene CHF 50'000'000 2⅛% Anleihe 2019-2024 (Valorennummer: 41'904'112, ISIN: CH0419041121, Ticker: SKS192) (die "SKS192 Obligationen"). Die SKS192 Obligationen haben einen Nennwert von je CHF 5'000 und werden am 20. Mai 2024 fällig.
Mit dem Rückkaufangebot bietet die Emittentin den Anleihegläubigern an, ihre SKS192 Obligationen gegen eine Barzahlung von 100,5% des Nennwerts jeder SKS192 Obligation zuzüglich aufgelaufener Zinsen bis zum voraussichtlich am 22. Dezember 2022 stattfindenden Vollzugstag des Rückkaufangebots anzudienen. Darüber hinaus erhalten Anleihegläubiger, die ihre SKS192 Obligationen gültig andienen, unabhängig vom Erfolg des Rückkaufangebots eine Zustimmungsgebühr (Consent Fee) in Höhe von 0,1% des Nennwerts einer SKS192 Obligation.
Das Rückkaufangebot unterliegt den Angebotsbeschränkungen, die im Informationsmemorandum (wie nachstehend definiert), das auf der Internetseite der Emittentin (www.schoen-klinik.de) verfügbar ist, dargelegt sind und durch Verweis hierin aufgenommen werden.
Das Rückkaufangebot beginnt am 1. Dezember 2022 und endet am 19. Dezember 2022, 12:00 Uhr MEZ ("Angebotsfrist"), vorbehaltlich des Rechts der Emittentin, das Rückkaufangebot zu ändern.
Das Rückkaufangebot unterliegt den folgenden Bedingungen:
- Es wurde kein Urteil, keine Verfügung oder sonstige behördliche Massnahme erlassen, die das Rückkaufangebot oder dessen Durchführung verbietet oder für rechtswidrig erklärt.
- Nach Abschluss des Rückkaufangebots hält die Emittentin mindestens 80% der SKS192 Obligationen ("Mindestannahmequote"), sodass die Emittentin die SKS192 Obligationen gemäss Art. 4(b) der Anleihebedingungen kündigen und die verbleibenden SKS192 Obligationen vorzeitig zum Nennwert zuzüglich aufgelaufener Zinsen (d.h. ohne Prämie) unter Einhaltung einer Kündigungsfrist von 30 Tagen zurückkaufen kann (Clean-up Call).
Die Emittentin behält sich das Recht vor, nach eigenem Ermessen jederzeit (i) die Angebotsfrist zu verlängern, (ii) einen der anderen im Rückkaufangebot genannten Termine zu ändern und/oder (iii) auf die Bedingung der Mindestannahmequote zu verzichten.
Eine solche Änderung des Rückkaufangebots wird mit ihrer Veröffentlichung auf der Internetseite der Emittentin (www.schoen-klinik.de), die auch nach Ablauf der Angebotsfrist erfolgen kann, wirksam.
Alle Veröffentlichungen im Zusammenhang mit dem Rückkaufangebot erfolgen rechtsgültig auf der Internetseite der Emittentin (www.schoen-klinik.de). Soweit anwendbar, werden die Veröffentlichungen auch gemäss den Ad hoc-Mitteilungspflichten der SIX Exchange Regulation erfolgen.
Das Informationsmemorandum im Zusammenhang mit dem Rückkaufangebot (das "Informationsmemorandum") ist auf der Internetseite der Emittentin (www.schoen-klinik.de) verfügbar. Die Anleihebedingungen der SKS192 Anleihen in deutscher Sprache sind bei der Helvetische Bank AG (der "Abwicklungsagent"), welche von der Emittentin als Abwicklungsagent (Tender Agent) im Zusammenhang mit dem Rückkaufangebot beauftragt wurde, kostenlos erhältlich (per E-Mail: prospectus@helvetischebank.ch oder per Telefon: +41 (0)44 204 56 19).
Diese Ad hoc-Mitteilung muss in Verbindung mit dem Informationsmemorandum gelesen werden. Das Informationsmemorandum enthält wichtige Informationen, die sorgfältig gelesen werden sollten, bevor eine Entscheidung in Bezug auf das Rückkaufangebot getroffen wird. Anleihegläubigern, die sich nicht sicher sind, welche Massnahmen sie ergreifen sollten, oder die sich über die Auswirkungen des Rückkaufangebots im Unklaren sind, wird empfohlen, sich unverzüglich von ihrem Effektenhändler, Bankberater, Anwalt, Buchhalter oder einem anderen unabhängigen Finanz-, Steuer- oder Rechtsberater beraten zu lassen, auch im Hinblick auf etwaige steuerliche Konsequenzen. Weder die Emittentin noch der Abwicklungsagent äussern sich hiermit zu den Bedingungen des Rückkaufangebots. Jede natürliche oder juristische Person, deren SKS192 Obligationen in ihrem Namen von einem Effektenhändler, einer Bank, Depotbank, Treuhandgesellschaft oder einem anderen Beauftragten oder Vermittler gehalten werden, muss sich mit diesem Unternehmen in Verbindung setzen, wenn sie ihre SKS192 Obligationen andienen möchte. Weder die Emittentin noch der Abwicklungsagent geben eine Empfehlung ab, ob Anleihegläubiger ihre SKS192 Obligationen andienen sollen.
NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA (THE "UNITED STATES") OR IN OR INTO OR TO ANY PERSON RESIDENT OR LOCATED IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS DOCUMENT
Ad-Hoc Notice pursuant to Art. 53 of the SIX Swiss Exchange Listing Rules
1 December 2022
SCHÖN KLINIK SE
(the "Issuer")
The Issuer launches today a voluntary tender offer (freiwilliges Rückkaufangebot) (the "Tender Offer") in relation to its CHF 50,000,000 2⅛% Bonds 2019-2024 (security number: 41'904'112, ISIN: CH0419041121, Ticker: SKS192) issued in 2019 (the "SKS192 Bonds"). The SKS192 Bonds have a nominal value of CHF 5,000 each and will mature on 20 May 2024.
With the Tender Offer, the Issuer is offering bondholders to tender their SKS192 Bonds against a cash payment of 100.5% of the nominal value of each SKS192 Bond plus accrued interest until the settlement date, expected to be 22 December 2022, of the Tender Offer. In addition, bondholders validly tendering their SKS192 Bonds will be paid a consent fee of 0.1% of the nominal value of a SKS192 Bond, regardless whether the Tender Offer will be successful or not.
The Tender Offer is subject to the offer restrictions set out in the Information Memorandum (as defined below) available on the website of the Issuer (www.schoen-klinik.de) which are incorporated herein by reference.
The Tender Offer commences on 1 December 2022 and ends on 19 December 2022, 12:00 a.m. CET ("Tender Offer Period"), subject to the right of the Issuer to modify the Tender Offer.
The Tender Offer is subject to the following conditions:
- No judgment, order or other authoritative measure has been issued which prohibits or declares the Tender Offer or the consummation thereof illegal.
- After completion of the Tender Offer, the Issuer holds at least 80% of the SKS192 Bonds (“Minimum Tender Quota Condition”) allowing the Issuer to cancel such SKS192 Bonds and early repay the remaining SKS192 Bonds at nominal value plus accrued interest (i.e. without premium) (Clean-up Call) in accordance with art. 4(b) of the terms of the SKS192 Bonds by giving 30 days prior notice.
The Issuer reserves the right in its sole discretion at any time (i) to extend the Tender Offer Period, (ii) to modify any of the other dates set forth in the Tender Offer, and/or (iii) to waive the Minimum Tender Quota Condition.
Any such modification of the Tender Offer shall become effective with its publication on the website of the Issuer (www.schoen-klinik.de) which may also occur after the end of Tender Offer Period.
All publications in connection with the Tender Offer will be validly made on the website of the Issuer (www.schoen-klinik.de). To the extent applicable, publications will also be made in line with the ad hoc disclosure requirements of SIX Exchange Regulation.
The information memorandum in connection with the Tender Offer (the "Information Memorandum") is avail-able on the website of the Issuer (www.schoen-klinik.de). The terms and conditions of the SKS192 Bonds in German language are available free of charge at Helvetische Bank AG (the "Tender Agent") (prospectus@hel-vetischebank.ch or phone +41 (0)44 204 56 19) who has been appointed by the Issuer as Tender Agent in connec-tion with the Tender Offer.
This ad-hoc notice must be read in conjunction with the Information Memorandum. The Information Memorandum contains important information which should be read carefully before any decision is made with respect to the Tender Offer. If any bondholder is in any doubt as to the action it should take or is unsure of the impact of the Tender Offer, it is recommended to seek its own financial and legal advice, including in respect of any tax consequences, immediately from its broker, bank manager, solicitor, accountant or other independent financial, tax or legal adviser. Neither the Issuer nor the Tender Agent expresses any opinion about the terms of the Tender Offer. Any individual or company whose SKS192 Bonds are held on its behalf by a broker, dealer, bank, custodian, trust company or other nominee or intermediary must contact such entity if it wishes to tender his/her SKS192 Bonds. Neither the Issuer nor the Tender Agent makes any recommendation whether bondholders should tender their SKS192 Bonds.